Eplerenone - Cardiovascular protection

被引：117

作者：

Brown, NJ

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN 37232 USA

来源：

CIRCULATION | 2003年 / 107卷 / 19期

关键词：

aldosterone; receptors; cardiovascular disease; hypertension; pharmacology;

D O I：

10.1161/01.CIR.0000071081.35693.9A

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Data from animal studies and clinical trials indicate that aldosterone causes cardiovascular and renal injury through mineralocorticoid receptor-dependent mechanisms. However, although aldosterone receptor antagonism reduces mortality in patients with congestive heart failure, the progestational and antiandrogenic side effects of the nonspecific aldosterone receptor antagonist, spironolactone, have limited its usefulness in the treatment of hypertension. This review provides an overview of the pharmacology, efficacy, and safety of a new, more selective aldosterone receptor antagonist, eplerenone, in the context of emerging concepts of the role of aldosterone in cardiovascular toxicity.

引用

收藏

页码：2512 / 2518

页数：7

相关论文

共 71 条

[1] ASSOCIATION OF THE RENIN SODIUM PROFILE WITH THE RISK OF MYOCARDIAL-INFARCTION IN PATIENTS WITH HYPERTENSION [J].

ALDERMAN, MH ;

MADHAVAN, S ;

OOI, WL ;

COHEN, H ;

SEALEY, JE ;

LARAGH, JH .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (16) :1098-1104

[2] ROLE OF ALDOSTERONE IN MYOCARDIAL INFARCTION [J].

ARORA, RB .

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1965, 118 (A11) :539-&

[3] CLONING OF HUMAN MINERALOCORTICOID RECEPTOR COMPLEMENTARY-DNA - STRUCTURAL AND FUNCTIONAL KINSHIP WITH THE GLUCOCORTICOID RECEPTOR [J].

ARRIZA, JL ;

WEINBERGER, C ;

CERELLI, G ;

GLASER, TM ;

HANDELIN, BL ;

HOUSMAN, DE ;

EVANS, RM .

SCIENCE, 1987, 237 (4812) :268-275

[4] EFFECTS OF ADDING SPIRONOLACTONE TO AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN CHRONIC CONGESTIVE-HEART-FAILURE SECONDARY TO CORONARY-ARTERY DISEASE [J].

BARR, CS ;

LANG, CC ;

HANSON, J ;

ARNOTT, M ;

KENNEDY, N ;

STRUTHERS, AD .

AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (17) :1259-1265

[5] Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes [J].

Beggah, AT ;

Escoubet, B ;

Puttini, S ;

Cailmail, S ;

Delage, V ;

Ouvrard-Pascaud, A ;

Bocchi, B ;

Peuchmaur, M ;

Delcayre, C ;

Farman, N ;

Jaisser, F .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) :7160-7165

[6] Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats [J].

Benetos, A ;

Lacolley, P ;

Safar, ME .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (06) :1152-1156

[7] ANGIOTENSIN-II-STIMULATED PROTEIN-SYNTHESIS IN CULTURED VASCULAR SMOOTH-MUSCLE CELLS [J].

BERK, BC ;

VEKSHTEIN, V ;

GORDON, HM ;

TSUDA, T .

HYPERTENSION, 1989, 13 (04) :305-314

[8] The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action [J].

Bhargava, A ;

Fullerton, MJ ;

Myles, K ;

Purdy, TM ;

Funder, JW ;

Pearce, D ;

Cole, TJ .

ENDOCRINOLOGY, 2001, 142 (04) :1587-1594

[9] Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension [J].

Blacher, J ;

Amah, G ;

Girerd, X ;

Kheder, A ;

Ben Mais, H ;

London, GM ;

Safar, ME .

AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (12) :1326-1334

[10] Aldosterone [J].

Booth, RE ;

Johnson, JP ;

Stockand, JD .

ADVANCES IN PHYSIOLOGY EDUCATION, 2002, 26 (01) :8-20

← 1 2 3 4 5 6 7 8 →